100050
1400W
A selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM).
Synonym(s):
1400W, N-(3-Aminomethyl)benzylacetamidine, 2HCl
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C10H15N3 · 2HCl
CAS Number:
Molecular Weight:
250.17
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Recommended Products
Quality Level
Assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated (hygroscopic)
color
white
solubility
water: 1 mg/mL
methanol: 5 mg/mL
shipped in
ambient
storage temp.
−20°C
InChI
1S/C10H16N3/c1-8(12)13-7-10-4-2-3-9(5-10)6-11/h2-5,13H,6-7,11-12H2,1H3/q+1/p+1
InChI key
FFSSUWWXUDLVQZ-UHFFFAOYSA-O
General description
A selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM). Suitable for use in both in vitro and in vivo systems. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
A selective, irreversible, slow, tight binding inhibitor of inducible nitric oxide synthase (iNOS, Kd = 7 nM) both in vitro and in vivo. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
Biochem/physiol Actions
Cell permeable: yes
Kd = 7 nM against inducible nitric oxide synthase (iNOS)
Primary Target
iNOS
iNOS
Product does not compete with ATP.
Reversible: no
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable up to 3 months at -20°C.
Other Notes
Parmentier, S., et al. 1999. Br. J. Pharmacol.127, 546.
Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M Marquina et al.
The British journal of dermatology, 159(1), 68-76 (2008-05-15)
Pemphigus vulgaris (PV) is a blistering autoimmune disease characterized by IgG autoantibodies against desmoglein 3. Nitric oxide synthases (NOS) may contribute to the increase of inflammation in tissues by the generation of nitrotyrosine residues (NTR). To investigate whether the production
Kento Tazawa et al.
The American journal of pathology, 190(12), 2417-2426 (2020-09-14)
Increased expression of the transient receptor potential ankyrin 1 (TRPA1) channel has been detected in carious tooth pulp, suggesting involvement of TRPA1 in defense or repair of this tissue after exogenous noxious stimuli. This study aimed to elucidate the induction
Martin Alejandro Krasnapolski et al.
Journal of cancer research and clinical oncology, 141(10), 1727-1738 (2015-02-18)
LM38 murine mammary adenocarcinoma model is formed by LM38-LP (myoepithelial and luminal), LM38-HP (luminal) and LM38-D2 (myoepithelial) cell lines. In a previous work, we had shown that LM38-HP and LM38-D2 cell lines are less malignant than the bicellular LM38-LP cell
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service